(Q41488659)

1 October 2017

title

Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System (English)

1 reference

1 October 2017

0 references

community mental health

1 reference

7

Stephen Bartels

1 reference

1 October 2017

Robert O Cotes

1

1 reference

1 October 2017

Alex de Nesnera

2

1 reference

1 October 2017

Michael Kelly

3

1 reference

1 October 2017

Karen Orsini

4

1 reference

1 October 2017

Haiyi Xie

5

1 reference

1 October 2017

Greg McHugo

6

1 reference

1 October 2017

Mary F Brunette

8

1 reference

1 October 2017

publication date

3 February 2015

1 reference

Community Mental Health Journal

1 October 2017

published in

1 reference

1 October 2017

volume

51

1 reference

1 October 2017

issue

6

1 reference

1 October 2017

page(s)

685-694

1 reference

Increasing off-label use of antipsychotic medications in the United States, 1995-2008

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Prediabetes assessment and follow-up in older veterans with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Metabolic monitoring of patients prescribed second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Audit and feedback: effects on professional practice and health care outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Healthcare barriers among severely mentally ill homeless adults: evidence from the five-site health and risk study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Monitoring for metabolic side effects among outpatients with dementia receiving antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Monitoring veterans for metabolic side effects when prescribing antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Metabolic screening in children receiving antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Physician patterns of metabolic screening for patients taking atypical antipsychotics: a retrospective database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

National trends in the office-based treatment of children, adolescents, and adults with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Adherence to guidelines for glucose assessment in starting second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

A case control study of the implementation of change model versus passive dissemination of practice guidelines for compliance in monitoring for metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10597-015-9833-0

To examine the extent of compliance to the proposed monitoring protocol among practicing psychiatrists for second generation antipsychotics

21 January 2018

1 reference

12 December 2020

Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children.

1 reference

12 December 2020

Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.

1 reference

12 December 2020

Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data.

1 reference

12 December 2020

Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care.

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

10.1007/S10597-015-9833-0

Identifiers

DOI

1 reference

Dimensions Publication ID

1 October 2017

1001261464

0 references

1 reference